| Medical and Health Sciences | Lifetime | 673 | CA 39 | 99.97 |
| Biological Sciences | Lifetime | 977 | CA 41 | 99.88 |
| Medical and Health Sciences | 2021-2025 | 471 | CA 15 | 99.90 |
| Surgery | Lifetime | 98 | CA 8 | 99.92 |
| Cardiology and Cardiovascular Medicine | Lifetime | 176 | CA 11 | 99.78 |
| Molecular Biology | Lifetime | 683 | CA 19 | 99.65 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 192 | CA 5 | 99.43 |
| Genetics | Lifetime | 354 | CA 18 | 99.18 |
| Clinical Biochemistry | Lifetime | 84 | CA 2 | 98.32 |
| Cancer Research | Lifetime | 499 | CA 16 | 96.89 |
| Surgery | 2021-2025 | 42 | CA 2 | 99.75 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 95 | CA 5 | 99.58 |
| Endocrinology, Diabetes and Metabolism | 2021-2025 | 125 | CA 7 | 98.12 |
| Cancer Research | 2021-2025 | 254 | CA 7 | 85.81 |
| Lipid metabolism and disorders | Lifetime | 8 | CA 1 | 99.74 |
| Cancer, Lipids, and Metabolism | Lifetime | 39 | CA 3 | 99.78 |
| Nuclear Structure and Function | Lifetime | 7 | CA 1 | 99.49 |
| Lipoproteins and Cardiovascular Health | Lifetime | 33 | CA 1 | 99.79 |
| Peroxisome Proliferator-Activated Receptors | Lifetime | 26 | CA 1 | 99.59 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 41 | CA 2 | 99.80 |
| RNA Research and Splicing | Lifetime | 128 | CA 5 | 99.41 |
| Cholesterol and Lipid Metabolism | Lifetime | 77 | CA 2 | 98.76 |
| Diabetes and associated disorders | Lifetime | 225 | CA 6 | 98.91 |
| Paraoxonase enzyme and polymorphisms | Lifetime | 12 | CA 1 | 98.59 |
| Liver Disease Diagnosis and Treatment | Lifetime | 777 | CA 20 | 99.04 |
| Metabolism and Genetic Disorders | Lifetime | 433 | CA 17 | 98.46 |
| Metabolism, Diabetes, and Cancer | Lifetime | 282 | CA 20 | 98.84 |
| Adipose Tissue and Metabolism | Lifetime | 544 | CA 26 | 98.61 |
| RNA regulation and disease | Lifetime | 186 | CA 7 | 98.07 |
| Caveolin-1 and cellular processes | Lifetime | 52 | CA 4 | 97.52 |
| Genomics and Rare Diseases | Lifetime | 198 | CA 10 | 98.11 |
| Genetic Associations and Epidemiology | Lifetime | 235 | CA 4 | 98.70 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 280 | CA 10 | 97.95 |
| Pancreatic function and diabetes | Lifetime | 730 | CA 37 | 98.04 |
| Pancreatitis Pathology and Treatment | Lifetime | 498 | CA 3 | 97.83 |
| Diet, Metabolism, and Disease | Lifetime | 540 | CA 28 | 97.45 |
| Cynara cardunculus studies | Lifetime | 28 | CA 1 | 96.37 |
| Pharmaceutical Economics and Policy | Lifetime | 451 | CA 36 | 94.99 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | Lifetime | 455 | CA 17 | 94.89 |
| Lipid metabolism and biosynthesis | Lifetime | 567 | CA 30 | 95.52 |
| Nutrition, Genetics, and Disease | Lifetime | 616 | CA 18 | 93.63 |
| Apelin-related biomedical research | Lifetime | 328 | CA 16 | 92.01 |
| Aortic Thrombus and Embolism | Lifetime | 120 | CA 7 | 90.34 |
| Cerebrovascular and genetic disorders | Lifetime | 501 | CA 14 | 83.83 |
| Lipid metabolism and disorders | 2021-2025 | 5 | CA 1 | 98.97 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 20 | CA 1 | 99.28 |
| Cancer, Lipids, and Metabolism | 2021-2025 | 30 | CA 2 | 99.16 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 32 | CA 2 | 99.34 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 404 | CA 34 | 96.22 |
| Peroxisome Proliferator-Activated Receptors | 2021-2025 | 42 | CA 2 | 91.59 |
| Caveolin-1 and cellular processes | 2021-2025 | 8 | CA 1 | 91.68 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 250 | CA 11 | 89.56 |
| Pancreatitis Pathology and Treatment | 2021-2025 | 650 | CA 4 | 89.97 |
| Hyperglycemia and glycemic control in critically ill and hospitalized patients | 2021-2025 | 142 | CA 2 | 87.51 |
| Cholesterol and Lipid Metabolism | 2021-2025 | 107 | CA 1 | 85.26 |
| Aortic Thrombus and Embolism | 2021-2025 | 17 | CA 1 | 84.94 |
| Genetic factors in colorectal cancer | 2021-2025 | 819 | CA 26 | 87.75 |
| Metabolism and Genetic Disorders | 2021-2025 | 522 | CA 14 | 85.23 |
| Diabetes and associated disorders | 2021-2025 | 818 | CA 22 | 86.65 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 804 | CA 38 | 81.42 |
| Nuclear Structure and Function | 2021-2025 | 379 | CA 7 | 67.71 |